Subsequently, Holmes et al. (2008) conducted a phase I clinical trial that presented the minimal toxicity of the AE37 (100, 500, 1000 μg) with GM-CSF (0, 30, 125, 250 μg) in 15 disease-free breast cancer patients (node-negative, HER immunohistochemistry 1–3 +). This evidence concerns the gene CSF2 and breast carcinoma.